|
1
|
Yaffee P, Osipov A, Tan C, Tuli R and
Hendifar A: Review of systemic therapies for locally advanced and
metastatic rectal cancer. J Gastrointest Oncol. 6:185–200.
2015.PubMed/NCBI
|
|
2
|
Harji DP, Griffiths B, Velikova G, Sagar
PM and Brown J: Systematic review of health-related quality of life
issues in locally recurrent rectal cancer. J Surg Oncol.
111:431–438. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Poulsen LØ, Qvortrup C, Pfeiffer P, Yilmaz
M, Falkmer U and Sorbye H: Review on adjuvant chemotherapy for
rectal cancer - why do treatment guidelines differ so much? Acta
Oncol. 54:437–446. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arezzo A, Passera R, Salvai A, Arolfo S,
Allaix ME, Schwarzer G and Morino M: Laparoscopy for rectal cancer
is oncologically adequate: A systematic review and meta-analysis of
the literature. Surg Endosc. 29:334–348. 2015. View Article : Google Scholar
|
|
5
|
Nussbaum N and Altomare I: The neoadjuvant
treatment of rectal cancer: A review. Curr Oncol Rep. 17:4342015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ghouti L, Pereira P, Filleron T, Humeau M,
Guimbaud R, Selves J and Carrere N: Pelvic exenterations for
specific extraluminal recurrences in the era of total mesorectal
excision: Is there still a chance for cure? A single-center review
of patients with extraluminal pelvic recurrence for rectal cancer
from March 2004 to November 2010. Am J Surg. 209:352–362. 2015.
View Article : Google Scholar
|
|
7
|
Guren MG, Undseth C, Rekstad BL,
Brændengen M, Dueland S, Spindler KL, Glynne-Jones R and Tveit KM:
Reirradiation of locally recurrent rectal cancer: A systematic
review. Radiother Oncol. 113:151–157. 2014. View Article : Google Scholar
|
|
8
|
Lotze MT and DeMarco RA: Dealing with
death: HMGB1 as a novel target for cancer therapy. Curr Opin
Investig Drugs. 4:1405–1409. 2003.
|
|
9
|
Süren D, Yildirim M, Demirpençe Ö, Kaya V,
Alikanoğlu AS, Bülbüller N, Yıldız M and Sezer C: The role of high
mobility group box 1 (HMGB1) in colorectal cancer. Med Sci Monit.
20:530–537. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Flohr AM, Rogalla P, Meiboom M, Borrmann
L, Krohn M, Thode-Halle B and Bullerdiek J: Variation of HMGB1
expression in breast cancer. Anticancer Res. 21:3881–3885.
2001.
|
|
11
|
Jiao Y, Wang HC and Fan SJ: Growth
suppression and radiosensitivity increase by HMGB1 in breast
cancer. Acta Pharmacol Sin. 28:1957–1967. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ohmori H, Luo Y and Kuniyasu H:
Non-histone nuclear factor HMGB1 as a therapeutic target in
colorectal cancer. Expert Opin Ther Targets. 15:183–193. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moriwaka Y, Luo Y, Ohmori H, Fujii K,
Tatsumoto N, Sasahira T and Kuniyasu H: HMGB1 attenuates
anti-metastatic defense of the lymph nodes in colorectal cancer.
Pathobiology. 77:17–23. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang C, Fei G, Liu Z, Li Q, Xu Z and Ren
T: HMGB1 was a pivotal synergistic effecor for CpG oligonucleotide
to enhance the progression of human lung cancer cells. Cancer Biol
Ther. 13:727–736. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Y, Zhang P, Wu Z, Chen J and Zhou Q:
Screening of highly-expressed-HMGB1-gene human lung cancer cell
lines. Zhongguo Fei Ai Za Zhi. 12:965–968. 2009.In Chinese.
|
|
16
|
Yang GL, Zhang LH, Bo JJ, Huo XJ, Chen HG,
Cao M, Liu DM and Huang YR: Increased expression of HMGB1 is
associated with poor prognosis in human bladder cancer. J Surg
Oncol. 106:57–61. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen J, Liu X, Zhang J and Zhao Y:
Targeting HMGB1 inhibits ovarian cancer growth and metastasis by
lentivirus-mediated RNA interference. J Cell Physiol.
227:3629–3638. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song B, Song WG, Li ZJ, Xu ZF, Wang XW,
Wang CX and Liu J: Effect of HMGB1 silencing on cell proliferation,
invasion and apoptosis of MGC-803 gastric cancer cells. Cell
Biochem Funct. 30:11–17. 2012. View
Article : Google Scholar
|
|
19
|
Zhang J, Liu C and Hou R: Knockdown of
HMGB1 improves apoptosis and suppresses proliferation and invasion
of glioma cells. Chin J Cancer Res. 26:658–668. 2014.
|
|
20
|
Gong W, Wang ZY, Chen GX, Liu YQ, Gu XY
and Liu WW: Invasion potential of H22 hepatocarcinoma cells is
increased by HMGB1-induced tumor NF-κB signaling via initiation of
HSP70. Oncol Rep. 30:1249–1256. 2013.PubMed/NCBI
|
|
21
|
Zhang J, Kou YB, Zhu JS, Chen WX and Li S:
Knockdown of HMGB1 inhibits growth and invasion of gastric cancer
cells through the NF-κB pathway in vitro and in vivo. Int J Oncol.
44:1268–1276. 2014.PubMed/NCBI
|
|
22
|
Sims GP, Rowe DC, Rietdijk ST, Herbst R
and Coyle AJ: HMGB1 and RAGE in inflammation and cancer. Annu Rev
Immunol. 28:367–388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang D, Loze MT, Zeh HJ and Kang R: The
redox protein HMGB1 regulates cell death and survival in cancer
treatment. Autophagy. 6:1181–1183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chang BP, Wang DS, Xing JW, Yang SH, Chu Q
and Yu SY: MiR-200c inhibits metastasis of breast cancer cells by
targeting HMGB1. J Huazhong Univ Sci Technolog Med Sci. 34:201–206.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu W, Zhang Z, Zhang Y, Chen X, Guo S,
Lei Y, Xu Y, Ji C, Bi Z and Wang K: HMGB1-mediated autophagy
modulates sensitivity of colorectal cancer cells to oxaliplatin via
MEK/ERK signaling pathway. Cancer Biol Ther. 16:511–517. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang J, Zhang R, Lu WW, Zhu JS, Xia LQ,
Lu YM and Chen NW: Clinical significance of hmgb1 expression in
human gastric cancer. Int J Immunopathol Pharmacol. 27:543–551.
2014.
|
|
27
|
Li ZJ, Song B, Liu J, Han JJ, Wang CX, Zhu
YX and Xu ZF: Inhibitory effect of silencing of HMGB1 gene
expression on the invasive and metastatic abilities of MGC-803
gastric cancer cells. Zhonghua Zhong Liu Za Zhi. 35:244–248.
2013.In Chinese. PubMed/NCBI
|
|
28
|
Zhang J, Zhu JS, Zhou Z, Chen WX and Chen
NW: Inhibitory effects of ethyl pyruvate administration on human
gastric cancer growth via regulation of the HMGB1-RAGE and Akt
pathways in vitro and in vivo. Oncol Rep. 27:1511–1519.
2012.PubMed/NCBI
|
|
29
|
Zhang X, Wang H and Wang J: Expression of
HMGB1 and NF-κB p65 and its significance in non-small cell lung
cancer. Contemp Oncol (Pozn). 17:350–355. 2013.
|
|
30
|
Wittwer C, Boeck S, Heinemann V, Haas M,
Stieber P, Nagel D and Holdenrieder S: Circulating nucleosomes and
immunogenic cell death markers HMGB1, sRAGE and DNAse in patients
with advanced pancreatic cancer undergoing chemotherapy. Int J
Cancer. 133:2619–2630. 2013.PubMed/NCBI
|
|
31
|
Wild CA, Brandau S, Lotfi R, Mattheis S,
Gu X, Lang S and Bergmann C: HMGB1 is overexpressed in tumor cells
and promotes activity of regulatory T cells in patients with head
and neck cancer. Oral Oncol. 48:409–416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li ML, Wang XF, Tan ZJ, Dong P, Gu J, Lu
JH, Wu XS, Zhang L, Ding QC, Wu WG, et al: Ethyl pyruvate
administration suppresses growth and invasion of gallbladder cancer
cells via downregulation of HMGB1-RAGE axis. Int J Immunopathol
Pharmacol. 25:955–965. 2012.
|
|
33
|
Livesey KM, Kang R, Zeh HJ III, Lotze MT
and Tang D: Direct molecular interactions between HMGB1 and TP53 in
colorectal cancer. Autophagy. 8:846–848. 2012. View Article : Google Scholar : PubMed/NCBI
|
